Dernek Hakkında Tıbbi Onkoloji Derneği Haberler

Journal of Clinical Oncology - Mart 2011

Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study
Raymond J. Osborne,  Virginia Filiaci,  Julian C. Schink,  Robert S. Mannel,  Angeles Alvarez Secord,  Joseph L. Kelley,  Diane Provencher,  David Scott Miller,  Allan L. Covens,  and Janice M. Lage JCO Mar 1, 2011:825-831; published online on January 24, 2011;10.1200/JCO.2010.30.4386.

Influence of Gynecologic Oncologists on the Survival of Patients With Endometrial Cancer
John K. Chan, Alexander E. Sherman, Daniel S. Kapp, Ruxi Zhang, Kathryn E. Osann, Larry Maxwell, Lee-May Chen, and Harshal Deshmukh
JCO Mar 1, 2011:832-838; published online on January 24, 2011;10.1200/JCO.2010.31.2124.

Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium
Richard Aplenc,  Susan M. Blaney,  Lewis C. Strauss,  Frank M. Balis,  Suzanne Shusterman,  Ashish Mark Ingle,  Shruti Agrawal,  Junfeng Sun,  John J. Wright,  and Peter C. Adamson
JCO Mar 1, 2011:839-844; published online on January 24, 2011;10.1200/JCO.2010.30.7231.

Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
Manish A. Shah,  Minaxi Jhawer,  David H. Ilson,  Robert A. Lefkowitz,  Edric Robinson,  Marinela Capanu,  and David P. Kelsen
JCO Mar 1, 2011:868-874; published online on December 28, 2010;10.1200/JCO.2010.32.0770.

Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer
Nancy E. Kemeny, William R. Jarnagin, Marinela Capanu, Yuman Fong, Alexandra N. Gewirtz, Ronald P. DeMatteo, and Michael I. D'Angelica
JCO Mar 1, 2011:884-889; published online on December 28, 2010;10.1200/JCO.2010.32.5977.

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi, D. Ross Camidge, Moacyr Ribeiro de Oliveira, Philip Bonomi, David Gandara, Divis Khaira, Christine L. Hann, Evelyn M. McKeegan, Elizabeth Litvinovich, Philip M. Hemken, Caroline Dive, Sari H. Enschede, Cathy Nolan, Yi-Lin Chiu, Todd Busman, Hao Xiong, Andrew P. Krivoshik, Rod Humerickhouse, Geoffrey I. Shapiro, and Charles M. Rudin
JCO Mar 1, 2011:909-916; published online on January 31, 2011;10.1200/JCO.2010.31.6208.

Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)
R. Timothy D. Oliver, Graham M. Mead, Gordon J.S. Rustin, Johnathan K. Joffe, Nina Aass, Robert Coleman, Rhian Gabe, Philip Pollock, and Sally P. Stenning
JCO Mar 10, 2011:957-962; published online on January 31, 2011;10.1200/JCO.2009.26.4655.

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo,  Michele Cavo,  Sara Bringhen,  Elena Zamagni,  Alessandra Romano,  Francesca Patriarca,  Davide Rossi,  Fabiana Gentilini,  Claudia Crippa,  Monica Galli,  Chiara Nozzoli,  Roberto Ria,  Roberto Marasca,  Vittorio Montefusco,  Luca Baldini,  Francesca Elice,  Vincenzo Callea,  Stefano Pulini,  Angelo M. Carella,  Renato Zambello,  Giulia Benevolo,  Valeria Magarotto,  Paola Tacchetti,  Norbert Pescosta,  Claudia Cellini,  Claudia Polloni,  Andrea Evangelista,  Tommaso Caravita,  Fortunato Morabito,  Massimo Offidani,  Patrizia Tosi,  and Mario Boccadoro
JCO Mar 10, 2011:986-993; published online on January 31, 2011;10.1200/JCO.2010.31.6844.
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012
Georgiana K. Ellis,  William E. Barlow,  Julie R. Gralow,  Gabriel N. Hortobagyi,  Christy A. Russell,  Melanie E. Royce,  Edith A. Perez,  Danika Lew,  and Robert B. Livingston
JCO Mar 10, 2011:1014-1021; published online on January 10, 2011;10.1200/JCO.2009.27.6543.

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
Nicolas Moosmann,  Ludwig Fischer von Weikersthal,  Ursula Vehling-Kaiser,  Martina Stauch,  Holger G. Hass,  Herrmann Dietzfelbinger,  Daniel Oruzio,  Stefan Klein,  Klaus Zellmann,  Thomas Decker,  Mathias Schulze,  Wolfgang Abenhardt,  Gerhard Puchtler,  Herbert Kappauf,  Johann Mittermüller,  Christopher Haberl,  Andreas Schalhorn,  Andreas Jung,  Sebastian Stintzing,  and Volker Heinemann
JCO Mar 10, 2011:1050-1058; published online on February 7, 2011;10.1200/JCO.2010.31.1936.

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Ronald B. Natale,  Sumitra Thongprasert,  F. Anthony Greco,  Michael Thomas,  Chun-Ming Tsai,  Patrapim Sunpaweravong,  David Ferry,  Clive Mulatero,  Robert Whorf,  Joyce Thompson,  Fabrice Barlesi,  Peter Langmuir,  Sven Gogov,  Jacqui A. Rowbottom,  and Glenwood D. Goss JCO Mar 10, 2011:1059-1066; published online on January 31, 2011;10.1200/JCO.2010.28.5981.

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
Richard H. de Boer,  Óscar Arrieta,  Chih-Hsin Yang,  Maya Gottfried,  Valorie Chan,  Johann Raats,  Filippo de Marinis,  Raymond P. Abratt,  Jürgen Wolf,  Fiona H. Blackhall,  Peter Langmuir,  Tsveta Milenkova,  Jessica Read,  and Johan F. Vansteenkiste
JCO Mar 10, 2011:1067-1074; published online on January 31, 2011;10.1200/JCO.2010.29.5717. [Abstract]

Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer
Charles M. Rudin,  Ann Mauer,  Martin Smakal,  Rosalyn Juergens,  Stanislav Spelda,  Michael Wertheim,  Andrew Coates,  Evelyn McKeegan,  Peter Ansell,  Xiangdong Zhou,  Jane Qian,  Rajendra Pradhan,  Barry Dowell,  Andrew Krivoshik,  and Gary Gordon
JCO Mar 10, 2011:1075-1082; published online on February 7, 2011;10.1200/JCO.2010.32.5944.

Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial
Patricia A. Ganz, Stephanie R. Land, Charles E. Geyer, Jr, Reena S. Cecchini, Joseph P. Costantino, Eduardo R. Pajon, Louis Fehrenbacher, James N. Atkins, Jonathan A. Polikoff, Victor G. Vogel, John K. Erban, Robert B. Livingston, Edith A. Perez, Eleftherios P. Mamounas, Norman Wolmark, and Sandra M. Swain
JCO Mar 20, 2011:1110-1116; published online on February 7, 2011;10.1200/JCO.2010.29.7689.

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study
Marco Colleoni,  Anita Giobbie-Hurder,  Meredith M. Regan,  Beat Thürlimann,  Henning Mouridsen,  Louis Mauriac,  John F. Forbes,  Robert Paridaens,  István Láng,  Ian Smith,  Jacquie Chirgwin,  Tadeusz Pienkowski,  Andrew Wardley,  Karen N. Price,  Richard D. Gelber,  Alan S. Coates,  and Aron Goldhirsch
JCO Mar 20, 2011:1117-1124; published online on February 14, 2011;10.1200/JCO.2010.31.6455.
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,  Luis Costa,  Francois Goldwasser,  Vera Hirsh,  Vania Hungria,  Jana Prausova,  Giorgio Vittorio Scagliotti,  Harm Sleeboom,  Andrew Spencer,  Saroj Vadhan-Raj,  Roger von Moos,  Wolfgang Willenbacher,  Penella J. Woll,  Jianming Wang,  Qi Jiang,  Susie Jun,  Roger Dansey,  and Howard Yeh
JCO Mar 20, 2011:1125-1132; published online on February 22, 2011;10.1200/JCO.2010.31.3304.

Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Athanassios Argiris, Michalis V. Karamouzis, William E. Gooding, Barton F. Branstetter, Shilong Zhong, Luis E. Raez, Panayiotis Savvides, and Marjorie Romkes
JCO Mar 20, 2011:1140-1145; published online on February 22, 2011;10.1200/JCO.2010.33.3591.

Successful Multifold Dose Escalation of Anti-GD2 Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study
Brian H. Kushner, Kim Kramer, Shakeel Modak, and Nai-Kong V. Cheung
JCO Mar 20, 2011:1168-1174; published online on February 22, 2011;10.1200/JCO.2010.28.3317.

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Mark Kirschbaum,  Paul Frankel,  Leslie Popplewell,  Jasmine Zain,  Maria Delioukina,  Vinod Pullarkat,  Deron Matsuoka,  Bernadette Pulone,  Arnold J. Rotter,  Igor Espinoza-Delgado,  Auayporn Nademanee,  Stephen J. Forman,  David Gandara,  and Edward Newman JCO Mar 20, 2011:1198-1203; published online on February 7, 2011;10.1200/JCO.2010.32.1398.

Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma
Georgia M. Beasley,  Jonathan C. Riboh,  Christina K. Augustine,  Jonathan S. Zager,  Steven N. Hochwald,  Stephen R. Grobmyer,  Bercedis Peterson,  Richard Royal,  Merrick I. Ross,  and Douglas S. Tyler
JCO Mar 20, 2011:1210-1215; published online on February 22, 2011;10.1200/JCO.2010.32.1224.

American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

Catherine H. Van Poznak,  Sarah Temin,  Gary C. Yee,  Nora A. Janjan,  William E. Barlow,  J. Sybil Biermann,  Linda D. Bosserman,  Cindy Geoghegan,  Bruce E. Hillner,  Richard L. Theriault,  Dan S. Zuckerman,  and Jamie H. Von Roenn
JCO Mar 20, 2011:1221-1227; published online on February 22, 2011;10.1200/JCO.2010.32.5209.